Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors.
Hoogenkamp DS, de Wit-van der Veen LJ, Huizing DMV, Tesselaar MET, van Leeuwaarde RS, Stokkel MPM, Lam MGEH, Braat AJAT. Hoogenkamp DS, et al. Among authors: tesselaar met. Curr Oncol Rep. 2024 May;26(5):551-561. doi: 10.1007/s11912-024-01521-w. Epub 2024 Apr 10. Curr Oncol Rep. 2024. PMID: 38598035 Free PMC article. Review.
The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.
Clement DSVM, van Leerdam ME, Tesselaar MET, Cananea E, Martin W, Weickert MO, Sarker D, Ramage JK, Srirajaskanthan R. Clement DSVM, et al. Among authors: tesselaar met. J Neuroendocrinol. 2024 Apr;36(4):e13376. doi: 10.1111/jne.13376. Epub 2024 Feb 22. J Neuroendocrinol. 2024. PMID: 38389192
Sarcopenia and Neuroendocrine Neoplasms.
Clement D, Brown S, Leerdam MV, Tesselaar M, Ramage J, Srirajaskanthan R. Clement D, et al. Among authors: tesselaar m. Curr Oncol Rep. 2024 Feb;26(2):121-128. doi: 10.1007/s11912-024-01494-w. Epub 2024 Jan 25. Curr Oncol Rep. 2024. PMID: 38270848 Review.
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
Dayton TL, Alcala N, Moonen L, den Hartigh L, Geurts V, Mangiante L, Lap L, Dost AFM, Beumer J, Levy S, van Leeuwaarde RS, Hackeng WM, Samsom K, Voegele C, Sexton-Oates A, Begthel H, Korving J, Hillen L, Brosens LAA, Lantuejoul S, Jaksani S, Kok NFM, Hartemink KJ, Klomp HM, Borel Rinkes IHM, Dingemans AM, Valk GD, Vriens MR, Buikhuisen W, van den Berg J, Tesselaar M, Derks J, Speel EJ, Foll M, Fernández-Cuesta L, Clevers H. Dayton TL, et al. Among authors: tesselaar m. Cancer Cell. 2023 Dec 11;41(12):2083-2099.e9. doi: 10.1016/j.ccell.2023.11.007. Cancer Cell. 2023. PMID: 38086335 Free article.
Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma.
Navran A, Al-Mamgani A, Elzinga H, Kessels R, Vens C, Tesselaar M, van den Brekel M, de Haan R, van Triest B, Verheij M. Navran A, et al. Among authors: tesselaar m. Clin Transl Radiat Oncol. 2023 Nov 4;44:100698. doi: 10.1016/j.ctro.2023.100698. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38021094 Free PMC article.
Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).
Ebbers SC, Barentsz MW, de Vries-Huizing DMV, Versleijen MWJ, Klompenhouwer EG, Tesselaar MET, Stokkel MPM, Brabander T, Hofland J, Moelker A, van Leeuwaarde RS, Smits MLJ, Braat AJAT, Lam MGEH. Ebbers SC, et al. Among authors: tesselaar met. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1121-1132. doi: 10.1007/s00259-023-06467-y. Epub 2023 Oct 28. Eur J Nucl Med Mol Imaging. 2024. PMID: 37897617 Free PMC article. Clinical Trial.
111 results